Patents by Inventor Kenji Matsuno

Kenji Matsuno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11059272
    Abstract: There is provided a polarizing plate, including: a polarizing layer having a thickness not greater than 20 ?m; a first protective film stacked on one surface of the polarizing layer, with a first adhesive layer formed from an active energy ray curing adhesive being interposed; and a second protective film stacked on the other surface of the polarizing layer, with a second adhesive layer formed from a water-soluble adhesive being interposed. There are also provided a polarizing plate with a pressure sensitive adhesive layer, a substrate having a polarizing plate bonded thereto, a liquid crystal display device, and an organic electroluminescence display device, all of which include the polarizing plate. Preferably, at least one of the first protective film and the second protective film has a moisture permeability not higher than 1000 g/m2/24 hr.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: July 13, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kenji Matsuno, Yuuhei Inokuchi
  • Patent number: 11043314
    Abstract: A conductive sheet capable of improving conductivity by suppressing reaggregation of carbon nanotubes, and a manufacturing method thereof are provided. Also, carbon composite paste and carbon composite filler are provided. The conductive sheet is characterized in that carbon nanotubes and carbon black as conductive materials are dispersed in a resin material. Carbon composite filler, which is composed of the carbon nanotubes in an amount of 10-30 wt. % and the carbon black in an amount of 90-70 wt. %, is dispersed uniformly in the resin material. The conductive sheet is composed of the carbon composite filler in an amount of 10-50 wt. % and the resin material in an amount of 90-50 wt. %, whose surface resistance value is 1-10 ?/sq.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 22, 2021
    Assignees: UNIVERSITY PUBLIC CORPORATION OSAKA, SEIWA ELECTRIC MFG. CO., LTD.
    Inventors: Shinichi Kitamura, Kenji Matsuno, Yukihiro Hijiri, Takeshi Horiguchi
  • Publication number: 20200130332
    Abstract: There is provided a polarizing plate, including: a polarizing layer having a thickness not greater than 20 ?m; a first protective film stacked on one surface of the polarizing layer, with a first adhesive layer formed from an active energy ray curing adhesive being interposed; and a second protective film stacked on the other surface of the polarizing layer, with a second adhesive layer formed from a water-soluble adhesive being interposed. There are also provided a polarizing plate with a pressure sensitive adhesive layer, a substrate having a polarizing plate bonded thereto, a liquid crystal display device, and an organic electroluminescence display device, all of which include the polarizing plate. Preferably, at least one of the first protective film and the second protective film has a moisture permeability not higher than 1000 g/m2/24 hr.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 30, 2020
    Inventors: Kenji MATSUNO, Yuuhei INOKUCHI
  • Patent number: 10549509
    Abstract: There is provided a polarizing plate, including: a polarizing layer having a thickness not greater than 20 ?m; a first protective film stacked on one surface of the polarizing layer, with a first adhesive layer formed from an active energy ray curing adhesive being interposed; and a second protective film stacked on the other surface of the polarizing layer, with a second adhesive layer formed from a water-soluble adhesive being interposed. There are also provided a polarizing plate with a pressure sensitive adhesive layer, a substrate having a polarizing plate bonded thereto, a liquid crystal display device, and an organic electroluminescence display device, all of which include the polarizing plate. Preferably, at least one of the first protective film and the second protective film has a moisture permeability not higher than 1000 g/m2/24 hr.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 4, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kenji Matsuno, Yuuhei Inokuchi
  • Publication number: 20170282506
    Abstract: There is provided a polarizing plate, including: a polarizing layer having a thickness not greater than 20 ?m; a first protective film stacked on one surface of the polarizing layer, with a first adhesive layer formed from an active energy ray curing adhesive being interposed; and a second protective film stacked on the other surface of the polarizing layer, with a second adhesive layer formed from a water-soluble adhesive being interposed. There are also provided a polarizing plate with a pressure sensitive adhesive layer, a substrate having a polarizing plate bonded thereto, a liquid crystal display device, and an organic electroluminescence display device, all of which include the polarizing plate. Preferably, at least one of the first protective film and the second protective film has a moisture permeability not higher than 1000 g/m2/24 hr.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 5, 2017
    Inventors: Kenji MATSUNO, Yuuhei INOKUCHI
  • Publication number: 20160368895
    Abstract: [Problem] The present invention addresses the problem of providing a compound that is useful for preventing or treating diseases associated with malfunctioning of PGI2 receptors, in particular, pulmonary hypertension. [Solution] A positive allosteric regulator of a PGI2 receptor which comprises a compound represented by formula (1) or a pharmaceutically acceptable salt, hydrate or solvate thereof. (1) (In the formula, R1 is a branched chain or cyclic alkyl or alkenyl having 3 to 10 carbon atoms which may be substituted, R2 is a hydrogen atom or an alkyl having 1 to 6 carbon atoms which may be substituted, R3 is 1 to 4 substituents which are the same or different independently selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl having 1 to 6 carbon atoms which may be substituted, and an alkoxy having 1 to 6 carbon atoms which may be substituted, and A is an aryl which may be substituted or a heteroaryl which may be substituted.
    Type: Application
    Filed: November 27, 2014
    Publication date: December 22, 2016
    Applicants: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Tetsuo NAGANO, Takayoshi OKABE, Hirotatsu KOJIMA, Toshifumi SUZUKI, Kenjiro HANAOKA, Manabu SHIMONISHI, Shinichiro EGASHIRA, Hirofumi NAKANO, Kazuo KUMAGAI, Hiroyuki MIYACHI, Kenji MATSUNO, Minoru WAKI
  • Publication number: 20160268017
    Abstract: A conductive sheet capable of improving conductivity by suppressing reaggregation of carbon nanotubes, and a manufacturing method thereof are provided. Also, carbon composite paste and carbon composite filler are provided. The conductive sheet is characterized in that carbon nanotubes and carbon black as conductive materials are dispersed in a resin material. Carbon composite filler, which is composed of the carbon nanotubes in an amount of 10-30 wt. % and the carbon black in an amount of 90-70 wt. %, is dispersed uniformly in the resin material. The conductive sheet is composed of the carbon composite filler in an amount of 10-50 wt. % and the resin material in an amount of 90-50 wt. %, whose surface resistance value is 1-10 ?/sq.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 15, 2016
    Applicants: OSAKA PREFECTURE UNIVERSITY, SEIWA ELECTRIC MFG. CO., LTD.
    Inventors: Shinichi KITAMURA, Kenji MATSUNO, Yukihiro HIJIRI, Takeshi HORIGUCHI
  • Publication number: 20160252660
    Abstract: There is provided a polarizing plate, including: a polarizing layer having a thickness not greater than 20 ?m; a first protective film stacked on one surface of the polarizing layer, with a first adhesive layer formed from an active energy ray curing adhesive being interposed; and a second protective film stacked on the other surface of the polarizing layer, with a second adhesive layer formed from a water-soluble adhesive being interposed. There are also provided a polarizing plate with a pressure sensitive adhesive layer, a substrate having a polarizing plate bonded thereto, a liquid crystal display device, and an organic electroluminescence display device, all of which include the polarizing plate. Preferably, at least one of the first protective film and the second protective film has a moisture permeability not higher than 1000 g/m2/24 hr.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 1, 2016
    Inventors: Kenji MATSUNO, Yuuhei INOKUCHI
  • Publication number: 20150133439
    Abstract: The Present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: July 9, 2014
    Publication date: May 14, 2015
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Patent number: 8796320
    Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: August 5, 2014
    Assignees: General Incorporated Association Pharma Valley Project Supporting Organization, Pharma Design, Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult Honsha
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
  • Publication number: 20130274252
    Abstract: The Present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 17, 2013
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Patent number: 8466290
    Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: June 18, 2013
    Assignees: Pharma IP General Incorporated Association, Pharma Design, Inc., Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult Honsha
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
  • Patent number: 8324205
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: December 4, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Publication number: 20120302524
    Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).
    Type: Application
    Filed: December 28, 2010
    Publication date: November 29, 2012
    Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, PHARMA DESIGN, INC., KABUSHIKI KAISHA YAKULT HONSHA, KUMAMOTO HEALTH SCIENCE UNIVERSITY, SHIZUOKA PREFECTURE
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
  • Patent number: 8022071
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: September 20, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Publication number: 20110172429
    Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: July 10, 2009
    Publication date: July 14, 2011
    Applicants: PHARMA IP GENERAL INCORPORATED ASSOCIATION, PHARMA DESIGN, INC., SHIZUOKA PREFECTURE, KUMAMOTO HEALTH SCIENCE UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
  • Publication number: 20100113468
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: May 22, 2009
    Publication date: May 6, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Patent number: 7560461
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: July 14, 2009
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Publication number: 20090176780
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: December 18, 2007
    Publication date: July 9, 2009
    Applicants: Millennium Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Nee Junko Irie Junko Sasaki, Shoji Oda
  • Patent number: 7329655
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomeruloscierosis.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: February 12, 2008
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda